

#### October 3, 2017

Chloe Bryson-Cahn MD
Robert Cybulski, PhD
Marisa D'Angeli, MD
Rupali Jain, PharmD
John Lynch, MD, MPH
Natalia Martinez-Paz, MA
Paul Pottinger, MD
Erica Stohs MD, MPH
Ted Wright, MD

#### Agenda

- Didactic: Interpreting Susceptibility Data
- Case Discussions
- Open Discussion

This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient.



#### Interpreting Susceptibility Data

Paul Pottinger, MD, FIDSA
Associate Professor
UW Medical Center &
The University of Washington School of Medicine

October 3, 2017

This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient.



#### **Disclosures**



- No financial conflicts of interest
- Everything we discuss is QI, thus protected from legal discovery under WA State Code



#### Question...

"When we see a bacterial isolate with "intermediate" sensitivity, should we treat it as being "resistant?"



- A. Yep
- B. Nope
- C. I'm not sure...


#### **Antimicrobial Susceptibility Testing**

- Qualitative (disk diffusion)
  - ✓ Susceptible, intermediate, resistant
- Quantitative (macro- or microdilution, E-test)
  - Minimal inhibitory concentration (MIC) is the lowest concentration of a given antimicrobial that prevents growth of the test organism
- Attempt to correlate in vitro growth inhibition with a clinical response to a specific antibiotic
  - Clinical Laboratory Standards Institute (CLSI) testing guidelines for each bug-drug combination
- ALL IGNORE HOST FACTORS & SPECIFIC CLINICAL SITUATIONS!



# Disk Diffusion (Qualitative)

"Kirby-Bauer-Turck" method.





# Disk Diffusion (Qualitative)

- "Kirby-Bauer-Turck" method.
- Antimicrobial impregnated disks placed on agar plate inoculated with standard concentration of microorganism.
- Measure zone of inhibition in millimeters.
- Zones are interpreted as sensitive, intermediate, or resistant based on CLSI criteria.
- Criteria vary by drug and bug.







FIG. 1. McFarland standards (left to right) 0.5, 1.0, 2.0, 3.0, positioned in front of a Wickerham card. McFarland standards are used to prepare bacterial suspensions to a specified turbidity. In the Kirby-Bauer disk diffusion susceptibility test protocol, the bacterial suspension of the organism to be tested should be equivalent to the 0.5 McFarland standard.




# Broth Dilution (Quantitative)

#### Determination of MIC (here: broth ditution test)






Macrobroth



Microbroth



# E-test (Quantitative)



# Quantitative Susceptibility Testing

- MIC = Minimum Inhibitory Concentration
  - ✓ A lower MIC means smaller amounts of drug are necessary to inhibit growth. That's good!
  - ✓ But... Lowest MIC does not necessarily mean that is the most effective drug in vivo
  - ✓ PK/PD properties of drug?
  - ✓ Drug toxicity... interactions... collateral damage... cost?







### Quantitative Susceptibility Testing


MIC = Minimum Inhibitory Concentration

✓ Expect variability of one dilution from run to run... in some cases, MICs predictably different in one assay than another (eg MRSA vanco MIC higher in Ę-test than

microbroth).



# Intermediate... Beyond "S" or "R"





1 0.5 0.25 0.13 0.06 0

Pre-Defined Interpretive Breakpoints

#### 2+ KLEBSIELLA PNEUMONIAE

	Microtiter MIC Interp	Microtiter MIC Value
Amikacin	s '	<=16
Ampicillin	R	>16
Ampicillin/Sulbactam	R	>16
Aztreonam	R	>8
Cefazolin	R	>16
Cefepime	R	>16
Cefotetan	I	32
Ceftazidime	R	>16
Ceftriaxone	R	>2
Ciprofloxacin	R	>2
Ertapenem	R	>1
Gentamicin	R	>8
Levofloxacin	R	>4
Meropenem	S	<=1
Piperacillin/Tazobactam	R	>64
Tigecycline		0.5
Tobramycin	R	>8
Trimeth Sulfamethoxazole R		>4



# Interpretive Breakpoints

The Limits of S/I/R

✓ "S" drugs usually work... if the host can mount a good immune response, and source is drained.



✓ "R" drugs sometimes work too... if body site concentrates the drug!





So... who decides "S" or "R" anyhow?

# Interpretive Breakpoints

Clinical Labs Standards Institute (Formerly NCCLS)







# Interpretive Breakpoints

# Clinical Labs Standards Institute (Formerly NCCLS)



- ✓ Well-Intentioned
- ✓ Multi-Disciplinary
- ✓ Standard distribution examined... but decision for "susceptible" ultimately arbitrary.
- ✓ Pharma at the table... good and problematic

"Intermediate" may represent gradual MIC creep... or political controversy.



#### **Conclusions**

"When we see a bacterial isolate with "intermediate" sensitivity, should we treat it as being "resistant?"





#### Conclusions

#### It totally depends!

- ✓ Drug concentration in body compartment?
- ✓ Synergy with other drugs?
- ✓ Do you have a better option?

This is the art of ID Medicine! If considering using an "I" drug, reasonable to consult ID.

